Objective To observe the inhibition effect of recombinant human monocyte chemoattractant protein－ 1(MCP－ 1) on implantation and growth of human osteosarcoma cells. Methods The method of protein fusion was used for the expression of MCP－ 1 in b.coli and then the MCP－ 1 was extracted and purified. Fifty nude mice were divided into 10 groups. For A1－ 4 groups, the 5 mice in each group were locally injected with doses of 1? g, 10? g, 100? g, 1 mg of MCP－ 1 at the same time when 4.4? 106 osteosarcoma cells were implanted in vivo. For B0－ 4 groups, 5 mice in each group, the injection were given 2 weeks later when there was the formation of the tumor mass at doses of 0? g(0.2 ml normal saline), 1? g, 10? g, 100? g, 1 mg of MCP－ 1 every other day. Five mice in group C were injected with dose of 0.2 ml NS as control. Results Implantation of osteosarcoma cells were completely prevented among mice of group A2－ 4, tumor inhibiting effect even in group A1 and the rate of tumor inhibition was 69.69％ . AKP values in mice of group A1－ 4 were much lower than those of group B0(P

Objective To study the effect of vascular endothelial growth factor (VEGF) containing fibrin glue(FG) on re-endotheliazation, cell proliferation and intimal hyperplasia in a canine model of carotid artery endothelium injury. MethodsThe effect of FG/VEGF/heparin versus FG alone treatment was evaluated at the time point of 10, 30, and 90 days by measuring the intima/media (I/M) ratio and cell proliferation by BrdU incorporation using immunohistochemistry. EC coverage was determined by SEM. ResultsCompared with normal saline control, FG/VEGF/heparin treatment significantly increased EC coverage at day 10 and at day 30 (P

Objective To evaluate the clinical effects of autogenous vein grafting for the treatment of atherosclerotic occlusion of the lower limbs. Methods Ninety cases of segemental atherosclerotic occlusion of the lower limbs underwent autogenous vein graft bridging procedures from Jan 2002 to Feb 2005 in our hospital. The immediate surgical results were compared with symptoms of pre-operation, and the long-term patency rate was evaluated. Results Total symptom relief was achieved in 87 cases, with the limbs pain disappearing, skin temperature going up, and the refractory ulcer tending to heal. There was a significant difference in ABI, perioperatively increasing from 0. 38?0. 11 to 0. 85?0. 18(P

Objective:To explore the application value of biomaterial breast model combined with traditional clinical teaching methods in the training of minimally invasive breast surgery.Methods:A total of 50 physicians who studied at the Thyroid and Breast Surgery Department of The First Affiliated Hospital of Air Force Medical University from March to December 2021 were selected as the research subjects and divided into the experimental group and the control group. The training time was one week, with three modules, namely, the study of Doppler ultrasound system and ultrasound theory, the study of the operating system for minimally invasive breast surgery, and the clinical observation and practice of minimally invasive breast surgery. Additionally, physicians in the experimental group practiced the surgical skills by using the biological material breast model. After the training, the assessment of breast minimally invasive surgery was performed, and the differences of minimally invasive operation and subjective evaluation of the two groups of physicians were analyzed. SPSS 22.0 was used to conduct independent-samples t-test and Chi-square test. Results:The time spent on breast mass localization, rotary cutter localization and residual rates of breast mass in the experimental group were (4.12±1.05) min, (12.12±2.61) min and 40%, respectively, and the corresponding results of the control group were (6.68±1.97) min, (15.32±2.89) min and 72%, which showed statistically significant differences between the two groups ( P<0.05). At the same time, the physicians in the experimental group were better than the control group in terms of self-evaluation of operational proficiency and clinical operation confidence. Conclusion:Compared with the traditional teaching method, the biomaterially simulated breast model combined with traditional teaching has significant advantages. It is an efficient teaching aid in the training and teaching of breast minimally invasive surgery, and plays an important role in the training of breast surgeons.

Since the Guangdong alliance launched the centralized procurement of Chinese patent medicine， manufacturers have engaged in fierce price competition to obtain the qualification for selection. In order to ensure that manufacturers have lowered the price without decreasing quality， the evaluation criteria for the quality of Chinese patent medicine is constructed on the basis of the characteristics of traditional Chinese medicine. The evaluation criteria consist of the production process and therapeutic effect evaluation. The evaluation indicators involve raw materials， processing and clinical use covering the whole life cycle of Chinese patent medicine. The evaluation of production process includes 3 secondary indicators （the quality of traditional Chinese medicine， the quality of traditional Chinese medicine decoction pieces and the quality of Chinese patent medicines） and 13 tertiary indicators （standardized production， quality inspection， processing specifications， technical processes， safety risk control， etc.）， which fully reflect the quality control of key links in the production of Chinese patent medicine. The therapeutic effect evaluation includes 5 secondary indicators （theoretical origin of formulation， proactive research by production enterprises， evidence-based medical evidence， clinical use， and technological embodiment） and 18 tertiary indicators （theoretical sources， post-market effectiveness re- evaluation， clinical guidelines， expert consensus， etc.） to assess the quality and efficacy of Chinese patent medicine from multiple perspectives and levels. This study is a useful supplement to the scheme of centralized procurement of Guangdong alliance， which can not only provide data support for selecting “low-cost and high-quality” Chinese patent medicine， but also provide information reference for hospitals to make procurement decisions.